Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of NSCLC tumors with high and low PAEP expression

ABSTRACT: Gene expression profiling of NSCLC tumors with high and low PAEP expression

PROVIDER: PRJNA475102 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiling of NSCLC tumors with high and low PAEP expression

Project description:Gene expression profiling of NSCLC tumors with distinct PAEP expression suggested several pathways, which might be involved in the regulation of PAEP/glycodelin expression.

2018-11-12 | GSE115457 | GEO

Gene expression profiles of NSCLC tumors

Project description:A custom microarray was used to measure the gene expression of NSCLC tumors. This represents a subset of samples which also have matched DNA copy number profiles from array CGH experiments 49 microdissected NSCLC tumor samples

2011-09-11 | E-GEOD-31799 | biostudies-arrayexpress

Gene expression profiles of NSCLC tumors

2011-09-12 | GSE31799 | GEO

DNA copy number profiles of NSCLC tumors

Project description:Whole genome tiling path array CGH was used to measure the copy number profiles of 271 NSCLC tumors 271 microdissected NSCLC tumors

2011-09-11 | E-GEOD-31798 | biostudies-arrayexpress

Expression profiling of AKTP primary tumors cells with high or low expression of Emp1

Project description:Expression profiling of AKTP primary tumors cells with high or low expression of Emp1

| PRJNA785641 | ENA

Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors

Project description:Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors

| PRJNA788281 | ENA

DNA copy number profiles of NSCLC tumors

Project description:Whole genome tiling path array CGH was used to measure the copy number profiles of 271 NSCLC tumors

2011-09-12 | GSE31798 | GEO

Expression profiling of AKTP primary tumors cells with high or low expression of Emp1

Project description:We sorted Emp1-tdTomato high and low cells from primary tumors grown in 4 different mice for 4 weeks

2022-09-16 | GSE190055 | GEO

Genomic changes in low vs high metastatic A549 NSCLC cell line

Project description:Genomic changes in low and highly metastatic A549 cells were analyzed by 500K SNP arrays. A large number of genomic alterations were present in A549 cells but no significant differences were observed between the low or highly metastatic A549 cell lines. We generated a NSCLC line with highly increased propensity to form tumor nodules in murine lungs after intravenous injections. Extravasation and growth at a distant site are important parts of the metastatic process and we regarded these as a surrogate marker for in vivo aggressiveness and potential metastatic capability. A549 lung asdenocarcimona cell line with initially low metastatic potential was used for this purpose; these cells formed multiple small nodules in NOD/SCID mice after first i.v.-injection, round 1 (R1). Removal of tumor nodules from the lungs and subsequent re-injection led to a rapid increase in metastatic capacity. A highly aggressive phenotype which was stable over time was evident after three rounds (R3) of in vivo selection for the A549 cell line.

2013-02-21 | E-GEOD-44549 | biostudies-arrayexpress

Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors

Project description:Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations do not respond to anti-PD-1 (L1) as well as tumors without an EGFR mutation. We showed in a xenograft mouse model of EGFR-mutated NSCLC that, neither durvalumab nor oleclumab alone inhibited tumor growth compared to the isotype control. In contrast, the combination of both antibodies significantly inhibited tumor growth and increased gene expressions that corresponded to inflammation and T cell function in tumors treated. We used microarrays to study gene expressions that corresponded to enhanced immune response in antibody-treated mice.

2022-02-23 | GSE190731 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data